Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright

ATOSSA THERAPEUTICS, INC.

2026-Q1 EPS reported -$1.11

Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.
R&D expenses $4.8M (+15% YoY) on increased clinical trial costs for (Z)-endoxifen; G&A $5.1M (+56%) due to $1.8M in patent litigation legal fees.
FDA granted Orphan Drug Designation (Jan 2026) and Rare Pediatric Disease designation for (Z)-endoxifen in Duchenne Muscular Dystrophy.
FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome (May 2026), eligible for Priority Review Voucher (sold for $100-205M).
Atossa strengthened leadership with two new Medical Directors: Dr. Puyana Theall (Breast Oncology) and Dr. Giwa (Rare Diseases).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-213439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.